These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27454112)

  • 1. Comparing domain interactions within antibody Fabs with kappa and lambda light chains.
    Toughiri R; Wu X; Ruiz D; Huang F; Crissman JW; Dickey M; Froning K; Conner EM; Cujec TP; Demarest SJ
    MAbs; 2016 Oct; 8(7):1276-1285. PubMed ID: 27454112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.
    Wu X; Sereno AJ; Huang F; Zhang K; Batt M; Fitchett JR; He D; Rick HL; Conner EM; Demarest SJ
    MAbs; 2015; 7(2):364-76. PubMed ID: 25611120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody Fab assembly: the interface residues between CH1 and CL.
    Padlan EA; Cohen GH; Davies DR
    Mol Immunol; 1986 Sep; 23(9):951-60. PubMed ID: 3097521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noncovalent association of heavy and light chains of human immunoglobulins. IV. The roles of the CH1 and CL domains in idiotypic expression.
    Rinfret A; Horne C; Dorrington KJ; Klein M
    J Immunol; 1985 Oct; 135(4):2574-81. PubMed ID: 3928754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach.
    Lehmann A; Wixted JH; Shapovalov MV; Roder H; Dunbrack RL; Robinson MK
    MAbs; 2015; 7(6):1058-71. PubMed ID: 26337947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the isotype of the light chain on the properties of IgG.
    Montaño RF; Morrison SL
    J Immunol; 2002 Jan; 168(1):224-31. PubMed ID: 11751966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Half molecular exchange of IgGs in the blood of healthy humans: chimeric lambda-kappa-immunoglobulins containing HL fragments of antibodies of different subclasses (IgG1-IgG4).
    Sedykh SE; Lekchnov EA; Prince VV; Buneva VN; Nevinsky GA
    Mol Biosyst; 2016 Oct; 12(10):3186-95. PubMed ID: 27506137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1.
    Malinge P; Chauchet X; Bourguignon J; Bosson N; Calloud S; Bautzova T; Borlet M; Laursen M; Kelpsas V; Rose N; Gueneau F; Ravn U; Magistrelli G; Fischer N
    MAbs; 2024; 16(1):2362432. PubMed ID: 38849989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An expanded genetic code facilitates antibody chemical conjugation involving the lambda light chain.
    Kato A; Ohtake K; Tanaka Y; Yokoyama S; Sakamoto K; Shiraishi Y
    Biochem Biophys Res Commun; 2021 Mar; 546():35-39. PubMed ID: 33561746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs.
    Burioni R; Bugli F; Mancini N; Rosa D; Di Campli C; Moroncini G; Manzin A; Abrignani S; Varaldo PE; Clementi M; Fadda G
    Virology; 2001 Sep; 288(1):29-35. PubMed ID: 11543655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability.
    Röthlisberger D; Honegger A; Plückthun A
    J Mol Biol; 2005 Apr; 347(4):773-89. PubMed ID: 15769469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional mapping of conserved residues located at the VL and VH domain interface of a Fab.
    Chatellier J; Van Regenmortel MH; Vernet T; Altschuh D
    J Mol Biol; 1996 Nov; 264(1):1-6. PubMed ID: 8950262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of heavy and light chain assembly by modification of heavy chain constant region 1 (CH1): Application for the construction of an anti-paclitaxel fragment antigen-binding (Fab) antibody.
    Yusakul G; Sakamoto S; Tanaka H; Morimoto S
    J Biotechnol; 2018 Dec; 288():41-47. PubMed ID: 30389640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between hybridoma and Fab/phage anti-RhD: their V gene usage and pairings.
    Perera WS; Moss MT; Urbaniak SJ
    Dis Markers; 2000; 16(1-2):15-9. PubMed ID: 11360822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of primate monoclonal antibodies to substitute for human antibodies: nucleotide sequence of chimpanzee Fab fragments.
    Ehrlich PH; Moustafa ZA; Harfeldt KE; Isaacson C; Ostberg L
    Hum Antibodies Hybridomas; 1990; 1(1):23-6. PubMed ID: 2129418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Basis of Enhanced Crystallizability Induced by a Molecular Chaperone for Antibody Antigen-Binding Fragments.
    Ereño-Orbea J; Sicard T; Cui H; Carson J; Hermans P; Julien JP
    J Mol Biol; 2018 Feb; 430(3):322-336. PubMed ID: 29277294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency.
    Tan PH; Sandmaier BM; Stayton PS
    Biophys J; 1998 Sep; 75(3):1473-82. PubMed ID: 9726949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of κ→λ light-chain constant-domain switch in the structure and functionality of A17 reactibody.
    Ponomarenko N; Chatziefthimiou SD; Kurkova I; Mokrushina Y; Mokrushina Y; Stepanova A; Smirnov I; Avakyan M; Bobik T; Mamedov A; Mitkevich V; Belogurov A; Fedorova OS; Dubina M; Golovin A; Lamzin V; Friboulet A; Makarov AA; Wilmanns M; Gabibov A
    Acta Crystallogr D Biol Crystallogr; 2014 Mar; 70(Pt 3):708-19. PubMed ID: 24598740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction of immunoglobulin heavy and light chains in the absence of the VH domain.
    Levo Y; Recht B; Michaelsen T; Franklin EC; Frangione B
    J Immunol; 1977 Aug; 119(2):635-40. PubMed ID: 407302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The eIg technology to generate Ig-like bispecific antibodies.
    Kühl L; Aschmoneit N; Kontermann RE; Seifert O
    MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.